Project Summary/Abstract: Alterations in the immune system occur with aging, likely contributing to the
development of infections and malignancies. Although the latter finding suggests an age-associated decline of
the immune system, aging could be regarded as a condition with dysregulated inflammation (inflammaging). In
T cell immunity, probably, the most prominent change with aging is the expansion of memory CD8+ T cells in
peripheral blood although its exact mechanism(s) and significance are yet to be determined. My lab
investigated whether the expansion of human memory CD8+ T cells with aging was secondary to increased
expression of IL-7 receptor alpha chain (IL-7Rα) which dictates the response to the pro-survival cytokine IL-7.
We found two cell populations which expressed low and high levels of IL-7Rα (IL-7Rαlow and high) in effector
memory (EM) CD8+ T cells in peripheral blood. Of interest, older adults (OA, age ≥ 65) had expansion of IL-
7Rαlow EM CD8+ T cells (up to 70% of total CD8+ T cells), which are largely cytotoxic and inflammatory cytokine
producing cells, compared to young adults (YA, age ≤ 40). Such cell expansion is associated with
cytomegalovirus infection, which persists for lifetime, as well as with enhanced production of and proliferative
response to IL-15 that promotes the maintenance and effector function of memory CD8+ T cells. However, the
significance of the expansion of IL-7Rαlow EM CD8+ T cells in OA remains largely unknown, especially in the
context of inflammation. To address this critical question, we performed a genome-wide DNA methylation
analysis in IL-7Rαlow and high EM CD8+ T cells since DNA methylation modulates gene expression. IL-7Rαlow
EM CD8+ T cells have hypomethylation of DNA in a group of chemotaxis-associated genes, including CX3CR1
(receptor for fractalkine), with enhanced expression. Plus, we noticed increased CX3CR1 expression by IL-
7Rαlow EM CD8+ T cells in OA compared to YA as well as the effect of aging on DNA methylation of the
CX3CR1 promoter in the same cells. Thus, we hypothesize that aging “qualitatively” enhances the pro-
inflammatory traits of human IL-7Rαlow EM CD8+ T cells by affecting gene regulatory mechanisms, including
DNA methylation and IL-15-mediated responses in addition to expanding them and that soluble factors
produced from such cells promote inflammation by activating other cells. This hypothesis will be tested with:
Aim 1. Investigate whether aging promotes IL-7Rαlow EM CD8+ T cell-mediated inflammatory response in
humans by altering inflammatory gene regulation via DNA methylation and transcription factors; Aim 2.
Elucidate age-associated alterations in IL-15-mediated inflammatory response in human IL-7Rαlow EM CD8+ T
cells; and Aim 3. Investigate the significance of age-associated alterations of IL-7Rαlow EM CD8+ T cells in
promoting inflammatory responses using ex vivo bioassay and humanized mice. Our results will shed light on
the biological significance of expanded memory CD8+ T cells with aging, especially in the aspect of
inflammation, as well as on the possible role of gene regulations in promoting this process.
Public Health Relevance Statement
Project Narrative
The goal of this proposal is to investigate whether and how aging affects CD8+ T cell-mediated inflammation as
well as the relationship of such findings with DNA methylation, transcription factors and tissue injury in older
adults. The results of these studies will advance our understanding in aging and inflammation, which can
adversely affect healthy aging.
No Sub Projects information available for 5R01AG056728-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AG056728-05
Patents
No Patents information available for 5R01AG056728-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AG056728-05
Clinical Studies
No Clinical Studies information available for 5R01AG056728-05
News and More
Related News Releases
No news release information available for 5R01AG056728-05
History
No Historical information available for 5R01AG056728-05
Similar Projects
No Similar Projects information available for 5R01AG056728-05